NCT05854810

Brief Summary

Polycystic ovarian syndrome (PCOS) is condition characterized by being complex, familial and polygenetic metabolic condition with heterogeneous involvement of several genes in the hypothalamic-pituitary-gonadal axis. PCOS is the most incident endocrine-metabolic syndrome that is characterized by hyperandrogenemia, menstrual irregularities, and/or small cysts in one or both ovaries and could be considered as the main cause of female infertility. Assisted reproductive technologies (ART) were defined by the American Center for Disease Control as any fertility-related treatments where eggs or embryos are manipulated. In vitro fertilization involves the transfer of fresh embryos, however, the freeze-all strategy that entails cryopreservation of all embryos to be transferred subsequently in un-stimulated cycle to guard against the negative effects of controlled ovarian stimulation on the endometrium and to minimize the risk of ovarian hyper-stimulation syndrome. Intracytroplasmatic sperm injection (ICSI) is a common procedure used to improve reproductive results, even among couples without male factor infertility. However, there are several points of controversy in the fields of ART traditionally, multiple embryo transfer strategy was used to increase the chance for getting a baby, however, multiple pregnancy is a common complication for this strategy with subsequent adverse fetal, maternal and neonatal outcomes. Also, the developmental stage of embryos at time of transfer; cleavage versus blastocyst was a matter of debit, but giving the chance for in-vitro maturation to the stage of blastocyst increased the possibility of getting good quality embryo to be transferred. However, the exaggeration of prolongation of the in-vitro duration appeared as a trend, but recent studies found no advantages for transfer of D7 or D6 blastocyst over D5 blastocyst transfer (BT).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
271

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 7, 2019

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 25, 2022

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

May 2, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 11, 2023

Completed
Last Updated

May 11, 2023

Status Verified

May 1, 2023

Enrollment Period

2.7 years

First QC Date

May 2, 2023

Last Update Submit

May 2, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • the live birth rate (LBR) after SBT and DBT

    9 months

Study Arms (2)

PCOS Patient

ACTIVE COMPARATOR
Procedure: fertilized embryo Insertion

Male factor infertility

ACTIVE COMPARATOR
Procedure: fertilized embryo Insertion

Interventions

insertion of single fertilized embryo through IVF

PCOS Patient

Eligibility Criteria

Age20 Years - 35 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Infertile women fulfilling at least two of the Rotterdam criteria for diagnosis of PCOS;
  • aged 20-35 years;
  • had body mass index (BMI) of less than 35 kg/m2;
  • mild hirsutism on Ferriman-Gallwey (FG) visual scoring system;
  • their hormonal profile of serum AMH \>4.5, FSH \<5.85 LH\>5.39;
  • had no previous attempts of ICSI were included in the study.

You may not qualify if:

  • Patients who were out of the predetermined age range and BMI;
  • had uterine abnormalities;
  • hydrosaplnix;
  • recurrent miscarriage;
  • medical diseases interfering with or being complicated by occurrence of pregnancy;
  • cases requiring ICSI with TESE samples;
  • had obesity-inducing endocrinopathy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zagazig University

Zagazig, Ash Sharqia Governorate, 44519, Egypt

Location

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor of gynecology

Study Record Dates

First Submitted

May 2, 2023

First Posted

May 11, 2023

Study Start

June 7, 2019

Primary Completion

March 5, 2022

Study Completion

July 25, 2022

Last Updated

May 11, 2023

Record last verified: 2023-05

Locations